Mutual Fund Details
NAV
₹467.6653
as on 10 May 2024, 11:13 PM
₹5.1219(1.11%)
Last Change
Scheme Ratings
5
Pharma
5Y Returns
4
rated by Value Research
Pharma
Rankings based on 5Y Returns | as on 13 May 2024
×
1
DSP Healthcare Fund Direct - Growth
28.19%
2
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
26.10%
3
Mirae Asset Healthcare Fund Direct - Growth
26.09%
4
SBI Healthcare Opportunities Fund Direct Plan-Growth
25.09%
5
Nippon India Pharma Fund Direct-Growth
24.68%
Schemes Managed By
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,45,797
₹1,49,790
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹49,790
Profit (absolute return)
49.79%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
1.03%
In the last 6 months
18.04%
In the last 1 year
49.81%
In the last 3 years
49.79%
In the last 5 years
201.66%
In the last 10 years
415.75%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 30 Apr 2024, 05:30 AM
₹7,132.82 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 1% if redeemed within 1 month.
0.92%
Expense Ratio
Plan
Growth
Benchmark
S&P BSE Healthcare Total Return Index
Exit Load
Exit load of 1% if redeemed within 1 month.
Scheme Document
Sectors Holding in this Mutual Fund
as on 30 Apr 2024
Healthcare
96.17%
₹6,859.63 Cr
Others
3.83%
₹273.19 Cr
Companies Holding in this Mutual Fund
as on 30 Apr 2024
Sun Pharmaceutical Industries Ltd.
13.81%
₹985.04 Cr
Lupin Ltd.
8.55%
₹609.86 Cr
Cipla Ltd.
6.08%
₹433.68 Cr
Apollo Hospitals Enterprise Ltd.
5.41%
₹385.89 Cr
Divi's Laboratories Ltd.
5.05%
₹360.21 Cr
Others
61.10%
₹4,358.15 Cr
View All
View All
Companies Holding in this Mutual Fund
as on 30 Apr 2024
Sun Pharmaceutical Industries Ltd.
13.81%
₹985.04 Cr
Lupin Ltd.
8.55%
₹609.86 Cr
Cipla Ltd.
6.08%
₹433.68 Cr
Apollo Hospitals Enterprise Ltd.
5.41%
₹385.89 Cr
Divi's Laboratories Ltd.
5.05%
₹360.21 Cr
Others
61.10%
₹4,358.15 Cr
View All
View All
This fund's returns:
14.40%Return Duration
3 Years
DSP Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
10.07%
17.08%
3Y Returns
17.08
SBI Healthcare Opportunities Fund Direct Plan-Growth
EquityPharma
Min. Investment
₹500
Category Returns
10.07%
17.08%
3Y Returns
16.45
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
10.07%
17.08%
3Y Returns
16.02
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date and is currently managed by its fund manager Sailesh Raj Bhan. It has an AUM of ₹7,132.82 Crores and the latest NAV decalared is ₹467.665 as on 13 May 2024 at 8:14 pm.
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 49.81%, in last 3 years is 49.79% and 569.39% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹7,132.82 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
View AMC Details
₹4,70,324.65 Cr
AUM
250
Schemes
Address
4th Floor, Tower A, Peninsula Business Park,Ganapatrao Kadam Marg, Lower Parel (W),400013
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
